慢性胰腺炎患者内镜逆行胰胆管造影术后胰腺炎的发生率与危险因素
该观察性队列研究分析了2011年1月至2015年5月一家三级医院慢性胰腺炎(CP)与胆道疾病(BD)患者的ERCP记录,共CP组1301例患者行2028例次ERCP、BD组1655例患者行2000例次ERCP。CP组与BD组术后胰腺炎(PEP)总体发生率相似(4.5% vs 4.8%,P=.747),但CP组中重度发作显著更低(0% vs 1.3%,P<.01)。按M-ANNHEIM分期,CP各期PEP发生率随疾病进展而下降,女性、急性胰腺炎病史和既往PEP为独立危险因素,体外冲击波碎石为保护因素。
要点
- CP组PEP总体发生率为4.5%,与BD组的4.8%相似(P=.747)。
- CP组中重度PEP发生率为0%,显著低于BD组的1.3%(P<.01)。
- CP患者PEP发生率随M-ANNHEIM分期进展而显著下降。
核心结论
- 与BD患者相比,CP患者PEP总体发生率相似,但严重程度分级更低。
- CP患者PEP发生率随疾病进展显著下降。
研究设计与样本
- 观察性队列研究,纳入2011年1月至2015年5月一家三级医院CP患者1301例(2028例次ERCP)和BD患者1655例(2000例次ERCP)。
- 采用χ2检验或Fisher精确检验比较CP组与BD组PEP发生率及CP不同临床分期的PEP风险,采用单因素和多因素分析探讨PEP的预测和保护因素。
- 临床试验注册号:NCT02781987。
主要发现
- CP组PEP总体发生率为4.5%,BD组为4.8%,两组相似(P=.747)。
- CP组中重度发作率为0%,BD组为1.3%,CP组显著更低(P<.01)。
- 按M-ANNHEIM分类,CP 0、I、II、III、IV期的PEP发生率分别为4.4%、5.1%、3.8%、2.0%、2.0%。
- CP Ia期患者PEP发生率最高(8.0%),显著高于Ib+Ic期(3.9%)和II期(3.8%)。
- 女性、急性胰腺炎病史和既往PEP为PEP独立危险因素,体外冲击波碎石为保护因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Almost all studies on post-ERCP pancreatitis (PEP) have mainly involved patients with biliary diseases rather than chronic pancreatitis (CP), and the concept that CP seems to be a protective factor associated with PEP has not been studied in detail. The aim of this study was to determine the incidence of PEP in patients with CP at different clinical stages and to identify the predictive and protective factors of PEP in a large cohort. METHODS: In this observational cohort study, medical records of patients with CP (CP group) and biliary diseases (BD group) in a tertiary hospital from January 2011 to May 2015 were examined. The difference in the incidence of PEP between CP group and BD group and the risk of PEP at different clinical stages of CP were calculated by the χ2 test or the Fisher exact test. The predictive and protective factors for PEP were investigated by univariate and multivariate analysis. RESULTS: In total, 2028 ERCP procedures were performed in 1301 patients with CP and 2000 procedures in 1655 patients with BD. The overall incidence of PEP in CP group (4.5%) was similar to that in the BD group (4.8%; P = .747). However, CP patients had significantly lower rates of moderate and severe attacks (0% vs 1.3%, P < .01). According to the M-ANNHEIM classification, the PEP incidences of CP at stages 0, I, II, III, and IV were 4.4%, 5.1%, 3.8%, 2.0%, and 2.0%, respectively. CP patients at stage Ia had the highest PEP incidence (8.0%) among all CP patients, significantly higher than that at stages Ib + Ic (3.9%) and II (3.8%). Female gender, history of acute pancreatitis, and prior PEP were independent risk factors of PEP, whereas extracorporeal shock wave lithotripsy was a protective factor. CONCLUSIONS: Compared with BD patients, CP patients had similar incidence of PEP overall but lower grades of severity. The incidence of PEP in CP patients decreased significantly with disease progression. (Clinical trial registration number: NCT02781987.).
引用
- Zhao ZH, Hu LH, Ren HB, et al. Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis. Gastrointest Endosc. 2017. PMID: 28062312. doi:10.1016/j.gie.2016.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。